Jon Arnason

8.6k citations
122 papers · 3.8k · 3 hit papers · h-index 28

Impact in

  • Oncology top 1%
    • CAR-T cell therapy research
  • Genetics top 1%
    • Chronic Lymphocytic Leukemia Research
    • Virus-based gene therapy research

Papers in

    • CAR-T cell therapy research 52
    • Biosimilars and Bioanalytical Methods 15
    • Immunodeficiency and Autoimmune Disorders 14
    • Immunotherapy and Immune Responses 7

Jon Arnason

116 papers receiving 3.8k citations

Jon Arnason's Hit Papers

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study 2022 · 209 citations
2090+6+12Years since publication200400600

Peers

Jon Arnason
Comparison fields: 5 of 93
  • Oncology 2.0k
  • Genetics 755
  • Immunology 1.3k
  • Pathology and Forensic Medicine 1.0k
  • Hematology 514
Replace Roland Repp with:
Roland Repp Germany
Javier Briones Spain
Maher K. Gandhi Australia
Lydia Visser Netherlands
Dirk Nagorsen United States
Justin Kline United States
William G. Morice United States
DG Maloney United States
Neil L. Berinstein Canada
Frank J. Hsu United States
Jon Arnason relative to Roland Repp Germany Roland Repp's profile →
Citations per field
00.5×8.5×
Roland Repp · 1×
Citations per year

Countries citing papers authored by Jon Arnason

Since Specialization
Citations

This map shows the geographic impact of Jon Arnason's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jon Arnason with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jon Arnason more than expected).

Fields of papers citing papers by Jon Arnason

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jon Arnason. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jon Arnason. The network helps show where Jon Arnason may publish in the future.

Co-authors

The 25 scholars most cited alongside Jon Arnason, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jon Arnason Line = papers co-authored together Jon Arnason links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 122 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease
Hit paper breakdown →
2007742
2
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
Hit paper breakdown →
2022435
3 2016233
4
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study
Hit paper breakdown →
2022209
5 2012136
6 2018132
7 2015110
8 202092
9 201990
10 201890
11 202188
12 202380
13 202176
14 202174
15 200171
16 201757
17 201556
18 202354
19 202047
20 201342

About Jon Arnason

Jon Arnason is a scholar working on Oncology, Immunology, Genetics, Pathology and Forensic Medicine and Hematology, having authored 122 papers that have together received 3.8k indexed citations. Recurring topics across this work include CAR-T cell therapy research (52 papers), Chronic Lymphocytic Leukemia Research (38 papers), Lymphoma Diagnosis and Treatment (31 papers), Biosimilars and Bioanalytical Methods (15 papers), Immunodeficiency and Autoimmune Disorders (14 papers), Chronic Myeloid Leukemia Treatments (11 papers), Glycosylation and Glycoproteins Research (7 papers) and Immunotherapy and Immune Responses (7 papers). The work is most often cited by research in Oncology (2.0k citations), Genetics (755 citations), Immunology (1.3k citations), Pathology and Forensic Medicine (1.0k citations) and Hematology (514 citations). Jon Arnason has collaborated with scholars based in United States, Germany and Israel. Frequent co-authors include Tim Sparwasser, Jeremy S. Abramson, Matthew A. Lunning, Gérard Eberl, Christoph Loddenkemper, Jennifer Freyer, Jochen Huehn, Alf Hamann, Hermann Wagner and Katharina Lahl. Their work appears in journals such as Blood, Journal of Clinical Oncology, Blood Advances, British Journal of Haematology and Transplantation and Cellular Therapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact